Variants in *SBF1, CELSR2,* and *TENM1* cause childhood epileptic encephalopathies

Yi-Wu Shi[1*], Jian-Guo Zhang[2,3*], Na He[1*], Zi-Long Ye[1], Wen-Bin Li[1], Han-Kui Liu[2,3], Zhi-Gang Liu[4], Nan-Xiang Shen[1], Xiao-Chong Qu[1], Cui-Xia Fan[1], Jie Wang[1], Sheng Luo[1], Yu-Dan Lv[5], Li Gao[6], Jing Chen[7], Shao-Ping Huang[8], Xin-Guo Lu[9], Jing Yu[10], Jie Zhang[11], Xiu-Xia Wang[12], Qu-Wen Gao[13], Li Jiang[14], Yan-Hui Chen[15], Hui Qi[6], Jing-Da Qiao[1], Li-Zhi Chen[1], Yuan-Jin Zeng[1], Xiao-Xue Yang[16], Hong-Jun Yan[17], Cheng-Yan Li[18], Tao Zeng[19], Fu-Li Min[19], Bing Qin[20], Hai-Qing Xu[21], Lin Xu[22], Bing-Mei Li[1], Yong-Hong Yi[1], Zhi-Hong Zhuo[23], Qing-Hui Guo[24], Su-Li He[25], Hong-Wei Zhang[26,27], Li-Ping Guan[2,3], Wei-Yi Deng[1], Xiao-Fan Ren[9], Dong-Fang Zou[9], Wei-Yue Gu[28], Tao Su[1], Xiao-Rong Liu[1], Yi-Bo Qu[29], Xin-Ping Yang[16], Wei-Ping Liao[1#]

Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China, 510260

BGI Genomics, Shenzhen 518083, China

Clin Lab, BGI Genomics, Shijiazhuang 050011, China

Affiliated Foshan Maternity and Child Healthcare Hospital, Southern Medical University, Foshan, China

The First Hospital of Jilin University, Jilin, China

Department of Pediatrics, Henan Province People's Hospital, People's Hospital of

Zhengzhou University, Zhengzhou, China

Department of Neurology, Children's Hospital of Nanjing Medical University, Nanjing, China

The Second Affiliated Hospital of Xi'an Jiaotong University, Xian, China

Shenzhen Children's Hospital, Shenzhen, China

Neurology Department, Children's Hospital of Xinjiang Uygur Autonomous Region, Urumchi, China

Hunan Provincial Children's Hospital, Changsha, China

The Second Hospital of Hebei Medical University, Shijiazhuang, China

Department of Neurology, Foresea Life Insurance Shaoguan Hospital, Shaoguan, China

Children's Hospital of Chongqing Medical University, Chongqing, China

Department of Pediatrics, Fujian Medical University Union Hospital, Fuzhou, China

Center for Genetics and Developmental Systems Biology, Nanfang Hospital, Southern Medical University, Guangzhou, China

Guangdong 999 Brain Hospital, Guangzhou, China

Affiliated Hospital of Guangdong Medical University, Zhanjiang, China

Guangzhou First People's Hospital, Guangzhou, China

The First Affiliated Hospital of Jinan University, Guangzhou, China

Xuzhou Center Hospital, Xuzhou, China

Qingdao Women and Children's Hospital, Qingdao, China

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

The Second Hospital of Shandong University, Jinan, China

Shantou Chaonan Minsheng Hospital, Shantou, China

Children's Hospital Affiliated to Shandong University, Jinan, China

Jinan Children's Hospital, Jinan, China

Chigene (Beijing) Translational Medical Research Center Co., Beijing, China

Key Laboratory of CNS Regeneration (Ministry of Education), Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Jinan University, Guangzhou, China

* These authors contributed equally to the manuscript.

Correspondence to Dr. Liao, Department of Neurology, Institute of Neuroscience, Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China, E-mail wpliao@163.net; liao@gzneurosci.com.

Abstract

Epileptic encephalopathy is a devastating epilepsy with etiologies that remain largely elusive, despite recent whole-gene/exon sequencing of large cohorts. This study targeted childhood epileptic encephalopathy, typically Lennox-Gastaut syndrome, which is characterized by age-dependent onset and characteristic clinical manifestations. Trio-based whole-exome sequencing was performed in 235 unrelated cases with individualized analysis by explainable inheritance origin with stratified frequency filtration and specified statistical analysis, including setting controls for

compound heterozygous variants. We identified three novel causative genes, including *SBF1* with *de novo* variants in three cases, *CELSR2* with recessive variants in eight cases, and *TENM1* with X-linked recessive variants in six cases. Significantly higher excesses of *de novo* variants in *SBF1* and biallelic variants in *CELSR2* and aggregated frequencies of variants in *SBF1*, *CELSR2*, and *TENM1* were detected. The frequency of compound heterozygous/homozygous *CELSR2* variants in the cases was significantly higher than that in 1942 asymptomatic parent controls. In *Drosophila*, knockdown of the three genes showed increased seizure-like behavior and increased firing of excitatory neurons. *Sbf1* knockout zebrafish showed seizure-like behavior, premature death, and increased firing of excitatory neurons. *Celsr2* knockout mice showed spontaneous seizures with epileptiform discharges. These results indicate that *SBF1*, *CELSR2*, and *TENM1* are pathogenic genes of Lennox-Gastaut syndrome.

Keywords

Lennox-Gastaut syndrome, childhood epileptic encephalopathies, *SBF1*, *CELSR2*, *TENM1*, trio-based whole-exome sequencing.

Introduction

Epileptic encephalopathies, also referred to as developmental and/or epileptic encephalopathies (DEEs)[1], represent a clinically and genetically heterogeneous group of devastating epilepsies characterized by refractory seizures, severe electroencephalography (EEG) abnormalities, and neurodevelopment delay or decline.

Epileptic encephalopathy is a common clinical entity and accounts for approximately 40% of newly diagnosed epilepsies before the age of three years[2]. According to onset age, epileptic encephalopathies can generally be divided into two major groups[1]: early infantile epileptic encephalopathy (EIEE) with onset in neonates or infants, such as West syndrome and Dravet syndrome, and childhood-onset epileptic encephalopathy, typically Lennox-Gastaut syndrome (LGS). LGS is estimated to account for 1%-2% of all patients with epilepsy and up to 10% of patients with childhood epilepsy[3-5]. It usually begins between 1 and 8 years old (before age 18 years) and is characterized by multiple seizure types that must include tonic seizures and/or consistent paroxysmal fast activity/polyspike on EEG[5]. The etiologies of epileptic encephalopathies remain largely elusive. Recent studies have demonstrated an increased number of genes associated with epileptic encephalopathies. To date, more than 100 genes have been reported to be associated with EIEE/DEEs (https://omim.org), explaining 22% to 40% of cases with EIEE[6,7]. In contrast, only a few genes, such as *CHD2*, *DNM1*, *GABRB3*, and *SYNGAP1*, have been identified in patients with LGS, accounting for a small proportion of cases[8-11]. Furthermore, recent studies with large cohorts have encountered challenges in discovering novel EIEE/DEE genes[12-14]. However, the age-dependent feature, specific clinical characteristics, and distinct EEG pattern highly suggest an underlying genetic mechanism in the epileptogenesis of LGS, which remains to be determined.

In the present study, we performed trio-based whole-exome sequencing (WES) in a cohort of patients with LGS without acquired etiologies. The potential pathogenic

variants were screened by an individualized analysis protocol, including individualized analysis on each trio by explainable inheritance origin with stratified frequency filtration and on each gene from four aspects that include gene expression in the brain, previously reported phenotypes, probability of being intolerant to heterozygous/homozygous variants of loss-of-function (pLI/pRec), and phenotypes produced by knockout/knockdown. Novel genes with repetitively identified *de novo* variants, biallelic variants, or hemizygous variants were selected for specified statistical analysis, including comparing the compound heterozygous variants with those in asymptomatic parent controls. Three genes were identified as novel candidate genes in this cohort, including *SBF1* with an autosomal dominant inheritance pattern (AD, *de novo* variants), *CELSR2* with autosomal recessive inheritance (AR), and *TENM1* with X-linked recessive inheritance (XLR). Animal models were used to validate the roles of the novel candidate genes in epilepsy. This study suggests that *SBF1*, *CELSR2,* and *TENM1* are pathogenic genes of LGS and highlights the implication of phenotype subclassification, individualized analysis of trios in combination with specified statistical analysis, and setting controls for compound heterozygous variants.

Methods

Subjects. A total of 235 unrelated cases (234 trios and 1 singleton) with Lennox-Gastaut syndrome (LGS) were enrolled from 2005 to 2021. Among these cases, 194 were long-term follow-up patients in the Epilepsy Center of the Second

Affiliated Hospital of Guangzhou Medical University. The other 41 patients were from 20 epilepsy centers of the First Hospital of Jilin University, Affiliated Foshan Maternity and Child Healthcare Hospital, Guangdong 999 Brain Hospital, Henan Province People's Hospital, Shenzhen Children's Hospital, Hunan Provincial Children's Hospital, The Second Affiliated Hospital of Xi'an Jiaotong University, Foresea Life Insurance Shaoguan Hospital, Children's Hospital of Nanjing Medical University, People's Hospital of Xinjiang Uygur Autonomous Region, The Second Hospital of Hebei Medical University, Affiliated Hospital of Guangdong Medical University, Guangzhou First People's Hospital, The First Affiliated Hospital of Jinan University, Xuzhou Center Hospital, Qingdao Women and Children's Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Hospital of Shandong University, Shantou Chaonan Minsheng Hospital, and Qilu Children's Hospital of Shandong University.

Detailed clinical information was collected, including sex, seizure onset age, seizure type and frequency, course of seizure, response to antiepileptic drugs, family history, and findings from general and neurological examinations. Brain MRI scans were performed to identify abnormalities in brain structure. Patients with acquired etiologies were excluded. Video EEG was examined, and the results were reviewed by two qualified electroencephalographers. Epileptic seizures and LGS were diagnosed and classified in accordance with the Commission on Classification and Terminology of the International League Against Epilepsy criteria (1989, 2001, 2010, 2017, and 2022). All patients were diagnosed with LGS with frequent seizures characterized by

two or more of the following features: (1) multiple seizure types including tonic seizures, (2) generalized polyspikes or fast rhythms during sleep (especially required when daily tonic seizures are obscure), and (3) generalized slow (< 2.5 Hz) spike-wave complex on EEG. The patients were followed up for at least one year. All subjects were Han Chinese with four Han Chinese grandparents and were born to nonconsanguineous Chinese parents.

This study adhered to the guidelines of the International Committee of Medical Journal Editors regarding patient consent for research or participation and received approval from the ethics committee of the Second Affiliated Hospital of Guangzhou Medical University. Written informed consent was obtained from the patients or their legal guardians.

Whole-exome sequencing. Genomic DNA was extracted from the peripheral blood obtained from the patients and their parents (trios) using the QIARamp Blood Mini Kit (Qiagen, Hilden, Germany). Trio-based whole-exome sequencing (WES) was performed on a HiSeq 2000 system (Illumina, San Diego, CA, USA) as previously reported[11,15]. The sequencing data were generated by massively parallel sequencing with > 100 times average depth and > 98% coverage of the capture regions, and the high-quality reads were mapped to the Genome Reference Consortium Human Genome build 37 (GRCh37) by Burrows-Wheeler alignment. Single-nucleotide variants and insert/deletion variants were called with the Genome Analysis Tool Kit.

Variant filtration and evaluation. To identify candidate causative variants in each trio, we adopted an individualized analytical framework in the following five steps (Fig. 1).

1. General filtration. The potentially pathogenic variants, including nonsense, frameshift, canonical splice site, initiation codon, in-frame insert/deletion, missense, and synonymous variants predicted to impact splicing, were retained and then filtered with minor allele frequency (MAF) < 0.005 in the Genome Aggregation Database (gnomAD).

2. Variant filtration by explainable inheritance origin in each trio. The origin of variants presents the genetic difference between the affected child and the parents and thus explains the occurrence of phenotype in a given family (trio), i.e., *de novo, recessive* from the two asymptomatic parents each, or hemizygous. Variants with an explainable inheritance origin in each trio were selected.

3. The variants were then filtered with stratified MAF criteria. The MAF of *de novo* variants, hemizygotes, and homozygotes is set as absent in the control populations in gnomAD, and for compound heterozygous variants, the product of multiplying the frequencies of two alleles in gnomAD is $< 1 \times 10^{-6}$, which is 7 times less than the probability of one individual in the current population of gnomAD ($1/141456 = 7 \times 10^{-6}$).

4. Variant filtration with criteria on the gene profile. The genes with selected variants were classified into epilepsy-associated genes (977 genes by Wang *et al.*[16] and updated from OMIM) and genes with undefined gene-disease/epilepsy/seizures

associations. For variants in epilepsy-associated genes, their pathogenicities were evaluated by the American College of Medical Genetics and Genomics Standards and Guidelines (ACMG)[17]. For those with undefined gene-disease/epilepsy/seizure associations, the following four aspects were assessed: (1) Tissue-specific expression: a candidate pathogenic gene should be expressed in the brain (inclusion criterion), with careful consideration of the possibility of other explainable pathogenic mechanisms, such as ectopic expression and remote toxic effects of abnormal metabolic products. (2) Excluding the disease-causing genes with previously defined gene-disease associations (including genotype-phenotype correlation) against the possibility of epilepsy as a phenotype (exclusion criterion). (3) The probability of being intolerant to heterozygous/homozygous variants of loss-of-function (pLI/pRec), genes of pLI ≥ 0.9 with repetitive *de novo* variants, and genes of pLI ≥ 0.9/pRec ≥ 0.9/pNull ≤ 0.1 with repetitive recessive variants were considered. (4) Whether the genetic knock-out/knock-down produce phenotypes of the brain.

5. The genes with repetitively identified (in two or more cases) *de novo*, recessive, and hemizygous variants were selected as novel candidate genes and were subjected to further statistical analysis, including excesses of *de novo* variants[8] and recessive variants[18], aggregate frequency of variants[19], and the frequency of the compound heterozygous variants compared with that in an asymptomatic parent control. In brief, for excess *de novo* variants, the *P*-value was calculated as [1-Poisson cumulative distribution function (χ-1, λ)], where χ is the observed *de novo* variant number for a specific gene, and λ is calculated as $2 \times 234 \times 1.2 \times 10^{-8} \times$ effective transcript

length of the gene on the autosome. For excess biallelic variants, the *P*-value was calculated as [1-cumulative binomial probability [(n-1, N, R)], where n is the observed biallelic variant number for a specific gene, N is the number of trios (234 in this cohort), and R is the rate of variants in the gene by chance in the population. The variants were filtered by different MAF cutoffs based on the class of variants, i.e., biallelic loss-of-function (LOF), one LOF and one damaging missense, and biallelic damaging missense. Considering that all patients were Han Chinese, the cutoff was set according to the MAF in the ExAC-East Asian population. For the aggregated frequency of variants, the controls include a cohort of 296 healthy Chinese volunteers as in our previous report[15] and the control populations in gnomAD. For compound heterozygous variants (two variants in trans), we established a control cohort that included 1942 asymptomatic parents from trios, in whom the compound heterozygous variants were identified by detecting one of the paired variants in the child, given that one of the paired variants in a parent would transmit to the child.

All candidate variants were validated by Sanger sequencing. Qualified novel candidate genes were subjected to further bioinformatics and experimental studies to define the gene-disease associations.

Protein structure modeling. The tertiary structure of the protein encoded by the novel candidate genes was modeled using trRosetta (https://yanglab.nankai.edu.cn/trRosetta/) to predict the effect of missense variants on protein structure. Hydrogen bonding was analyzed and visualized using PyMOL 2.3

software (https://pymol.org/2/).

Functional studies on *SBF1*, *CELSR2*, and *TENM1*. The use of animals and all experimental procedures were approved by the Committee for Animal Care of the Second Affiliated Hospital of Guangzhou Medical University.

Fly stocks. Flies were fed standard cornmeal and maintained in an incubator at 25 °C and 60%-70% humidity on a 12:12-hr light/dark cycle as previously described[15]. The *Drosophila* homologs of the human *SBF1*, *CELSR2*, and *TENM1* genes are *Sbf* (CG6939), *Flamingo* (CG11895), and *Ten-m* (CG5723), respectively. *UAS-Sbf-RNAi* (FBgn0025802), *UAS-Flamingo-RNAi* (FBgn0024836), and *UAS-Ten-m-RNAi* (FBgn0004449) were purchased from the Tsing Hua Fly Center (Tsinghua University, Beijing, China). The Gal4 driver lines *tub-Gal4* and *Canton-S* were gifts from Prof. LIU Ji-Yong (Guangzhou Medical University, Guangzhou, China). Virgin *tub-GAL4* females were mated with males of each RNAi line to establish flies with specific gene knockdown. The RNAi efficiency of the three genes in flies was detected by reverse transcription quantitative PCR (RT-qPCR). *Canton-S* was used as the WT line in this study.

Seizure behavior test in flies. The *tub-Gal4* line was crossed with *Sbf-*, *Flamingo-*, and *Ten-m-RNAi* to establish globally corresponding gene knockdown flies (*tub-Gal4>Sbf-RNAi*, *tub-Gal4>Flamingo-RNAi*, and *tub-Gal4>Ten-m-RNAi*,

respectively)[20]. The bang-sensitivity (BS) test was carried out on flies 3-5 days after eclosion, and seizure-like behavior was evaluated as described in previous studies[15,21]. Briefly, flies were anesthetized with CO_2 and transferred into a new clean food vial one day before testing. Three to six flies were placed in one vial and mechanically stimulated with a vortex mixer (VWR, Radnor, PA, USA) at maximum speed for 20 sec. The percentage and duration of BS paralysis in flies were recorded.

Electrophysiological assay on flies. Attached recording was performed in the knockdown and control flies using an established electrophysiological method[22]. Fly brains were dissected as previously described[23], transferred to a recording chamber with fly external solution, and immobilized with a C-sharp holder. The anterior side of the brain was positioned facing upward to enable observation of the soma of projection neurons (PNs) on the brain surface. The standard external solution contained 101 mM NaCl, 1 mM $CaCl_2$, 4 mM $MgCl_2$, 3 mM KCl, 5 mM glucose, 1.25 mM NaH_2PO_4, and 20.7 mM $NaHCO_3$ (pH 7.2, 250 mOsm). Attached recording was done by the Axon MultiClamp 700B amplifier with internal solution (contained 102 mM K-gluconate, 0.085 mM $CaCl_2$, 1.7 mM $MgCl_2$, 17 mM NaCl, 0.94 mM EGTA, and 8.5 mM HEPES (pH 7.2, 235 Osm)) filled glass pipettes (10-14 MΩ). Data were acquired with a Digidata 1440B digital–analog converter (Molecular Devices, San Jose, CA, USA) and pClamp v10.5 software (Molecular Devices, San Jose, CA, USA).

Generation of sbf1 knockout zebrafish using CRISPR-Cas9. The AB strain zebrafish (provided by Dr. Yang Xin-Ping of Southern Medical University) embryos and larvae were maintained on a 14:10-hr light/dark cycle and raised as previously described[24]. The larvae were allowed to develop at 28.5 °C and were staged by hours or days after fertilization under standard conditions. CRISPR-Cas9 genomic editing was used to generate *sbf1* knockout zebrafish as described previously[25]. The CRISPR target sequence (5'-AGTGGATGGCAGCTGGCTCC-3') and oligonucleotide were designed using ZiFit software[26]. The *sbf1*-targeting single-guide RNA (sgRNA) template plasmid was generated by annealing oligonucleotides and ligation of the double-stranded DNA in the plasmid PMD-18T (Takara, 6011) and then transcribed *in vitro* with T7 RNA polymerase (Thermo Fisher, # EP0111). A 1 nL mixture containing approximately 300 ng/µL Cas9 protein (New England Biolabs, Beverly, MA) and 15 ng/µL sgRNA was injected into one-cell stage embryos using a Picospritzer III pressure ejector. Germline mutations with a 4-nt deletion were introduced in the third coding exon of the *sbf1* gene. The mutant was verified by PCR-Sanger sequencing with dF1/dR1 primers.

The expression level of *sbf1* was detected in 5 days postfertilization (d.p.f) larvae by quantitative real-time PCR (RT-qPCR) using primers gF1/gR1 and dF2/dR2 and SYBR Premix Ex Taq (Takara, Japan) on an Mx3005P qPCR System (Agilent, USA). The primer sequences are listed in Supplementary Table 13.

Morphological, survival, and behavioral analysis of sbf1 knockout zebrafish. The

morphological and survival features of zebrafish from 0 to 30 d.p.f. were observed

and photographed using an Olympus microscope (BX51, Olympus, Japan). Abnormal

morphological phenotypes, including curved body and abdominal swelling, were

observed. The survival percentage of zebrafish of each genotype was calculated using

Kaplan-Meier survival analysis. For locomotion tracking, 6-9 d.p.f. larvae were

placed in individual wells of a 96-well flat-bottomed culture dish (Corning,

#07-200-565). Each well contained approximately 200 µL Ringer's solution and one

larva. Behavior was monitored at 28.5 °C using a ZebraBox system (ViewPoint

Behavior Technology) and was then analyzed using Zebralab locomotion tracking

software (ViewPoint Behavior Technology). After 10 min of habituation, each larva

was recorded for a total of 5 min with 5 light/dark cycles (each consisting of 10 sec on

light and 50 sec off light), followed by 60 min of recording. We then calculated the

traveled distance, duration, and numbers of rapid whirlpool-like circling swimming

with high speed (> 20 mm/sec, characterized as seizure behavior)[27]. Videos were

analyzed blindly for the classification of seizure behavior.

Electrophysiological assay on zebrafish. Electrophysiological recordings in zebrafish

were obtained using the methods described in the literatures[27,28]. Briefly, 7-11 d.p.f.

zebrafish larvae were embedded in a 1.2% agarose gel prepared by dissolving

low-melting temperature agarose in artificial cerebrospinal fluid (aCSF) (NaCl 134

mM, KCl 2.9 mM, MgCl2 1.2 mM, CaCl2 2.1 mM, glucose 10 mM, and HEPES 10

mM) with anesthetic agent (α-bungarotoxin, 1 mg/mL, Sigma). Then, fish were

placed on the upright stage of an Olympus microscope and perfused with standard recording solution. A glass microelectrode (~1 μm tip diameter, 2-7 MΩ) was placed in the optic tectum of the fish under visual guidance. Electrodes were filled with 2 M NaCl, and electrical activity was recorded using a 700B amplifier. Traces were bandpass filtered (0.2-1 kHz). A detection threshold of three times background noise was applied to extract the events on a 5-minute-long window. Detected events were manually sorted. Two or more consecutive spikes with a threshold of three times the background noise were considered seizure-like events in a 20-minute-long window. The time and duration of each event were extracted to evaluate seizure-like electrophysiology.

Behavior monitoring and electroencephalography (EEG) recording in Celsr2[-/-] mice. *Celsr2[-/-]* mice were generated as previously described[29] and provided by Dr. Yibo Qu (Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Jinan University). All mice were obtained by breeding *Celsr2[+/-]* males with *Celsr2[+/-]* females and maintained on a 12-hr light/dark cycle (lights on at 8:00 am, off at 8:00 pm) with food and water *ad libitum*. At three weeks old, the mice were placed into opaque home cages under 24-hr video monitoring for 7 days.

EEGs were recorded in *Celsr2[-/-]* and wild-type mice with free behavior for analysis of epileptic seizures, according to a previous study[30]. Briefly, the mice were anesthetized by 2% isoflurane (vol/vol) and implanted with a Teflon-coated silver wire electrode in the cortex (1.5 mm posterior and 1.2 mm lateral to the bregma) for

signal capture. The EEG signal was synchronized with a USB video camera to analyze epileptic seizure-like behavior. EEG signals were amplified with a preamplifier and primary amplifier (EX1, Dagan) and sampled at 10000 Hz (gain, 1000; bandpass filter, 0.1 to 500 Hz). Epileptic seizures were identified by checking both the EEG signal and the behavior of the animals. The incidence of seizures was calculated as previously described[31].

Statistical analysis. The two-tailed Fisher's exact test was used to compare the allele frequencies between the case and control groups. Data from experiments were first tested for Gaussian distribution. For normally distributed data, Student's t test and one-way analysis of variance (ANOVA) with Tukey's post hoc test were used to compare differences among two or more groups. For the data that were nonnormally distributed, the Mann-Whitney test and Kruskal-Wallis test were used to compare differences among two and multiple groups, respectively. Kaplan-Meier survival curves were compared using log-rank statistics. All testing was conducted by experimenters blinded to animal genotypes and analyzed by using GraphPad Prism 8.2 (La Jolla, CA, USA). *P* values less than 0.05 were considered statistically significant. Analysis of the excess of *de novo* and biallelic variants in a specific gene was performed according to previous reports[8,18] (detailed above in **Variants filtration and evaluation**). Bonferroni correction for *P*-values was applied for analysis of the excesses of variants. Given the general number of encoding genes in the human genome (19,711), a corrected *P* value (*Pc*) less than 2.54×10^6 (0.05/19,711)

indicated a significant genome-wide difference.

Results

General information from WES. We recruited 234 unrelated trios and a singleton (adopted) from 21 hospitals (Supplementary Table 1). The 235 patients included 164 boys and 71 girls, with an average onset age of 4.6 years old (4.6 ± 3.8, mean ± SD). On average, 5.9 Gb of the sequence was produced within the exome-targeted regions in each individual, with an average coverage of 120 depths (Supplementary Table 2). To identify potential novel pathogenic variants, we employed an individualized analytical framework that includes analyses on each trio by explainable inheritance origin and stratified minor allele frequency (MAF) filtration and analyses on the gene profile in four aspects (Fig. 1). After variant filtration by inheritance origin and MAF (steps 2 and 3 in Fig. 1), we obtained 1112 qualified variants in 930 genes, including 177 single *de novo* (15.9%), 77 homozygous (6.9%), 725 compound heterozygous (65.2%), and 133 hemizygous variants (12%) (Supplementary Table 3 and Extended Data Fig. 1a). The average number of variants per case was 4.8, including 0.8 *de novo* (ranging from 0 to 4), 0.3 homozygous (ranging from 0 to 5), and 3.1 compound heterozygous variants (ranging from 0 to 10); the number of hemizygous variants per male case was 0.8 (133/163, ranging from 0 to 5) (Extended Data Fig. 1b).

Potential pathogenic variants in epilepsy-associated genes. For known epilepsy-associated genes, variants were identified in 53 cases with 31 genes involved

(Table 1 and Supplementary Table 4). Among these variants, 47 single *de novo* variants in 26 genes were evaluated as pathogenic or likely pathogenic by using American College of Medical Genetics and Genomics (ACMG) standards, explaining 20% of cases (47/235) in this cohort. These genes are associated with epilepsy/DEE or developmental disorders with seizures (Table 1). The *CHD2* gene appeared to be the top gene, with 10 patients affected (4.3%, 10/235).

It was noted that the pathogenic/likely pathogenic variants estimated by ACMG were all *de novo*. In contrast, 6 recessive variants were evaluated as uncertain significance by ACMG (Table 1), including 2 homozygous, 1 compound heterozygous, and 3 hemizygous variants. Given that ACMG evaluates each of the paired biallelic variants separately and does not consider the specific dose effect of hemizygous variants, the pathogenicity of these variants was re-evaluated. These variants were considered to be possibly pathogenic by highly consistent clinical phenotype, as previously reported, absence or very low MAF in the general population (criteria in step 3 in Fig. 1), and explainable inheritance origin (Supplementary Table 4).

Repetitiveness of potential pathogenic variants in novel candidate genes. For variants in genes that have not been previously reported to be associated with epilepsy/seizures, further filtration of the gene profile was performed (step 4 in Fig. 1). Repetitive variants were identified in 29 genes with 73 cases involved (Table 1 and Supplementary Table 5). These genes met the inclusion criterion and the exclusion criterion as novel candidate genes, among which 12 genes met the additional two

criteria of a high probability of being intolerant to heterozygous/homozygous variants of loss-of-function (pLI/pRec) and abnormal phenotypes produced by knockout/knockdown (KO/KD). In addition, variants were identified in 26 genes that also met the four criteria on the gene profile but appeared in only a single case in this cohort (Supplementary Table 6). These patients had no other pathogenic or likely pathogenic variants in known or novel candidate epilepsy genes.

For genes with *de novo* variants, the Poisson cumulative distribution function was calculated[8]. *SBF1* presented a significant excess of *de novo* variants in this cohort, which was significant after Bonferroni corrections (Pc = 0.012, Table 1 and Supplementary Table 7). In addition, among the 26 epilepsy-associated genes with *de novo* variants, significant excesses were detected in *CHD2* and *SETD1B* ($Pc < 0.001$ and $Pc = 1.34 \times 10^{-5}$, respectively, Table 1 and Supplementary Table 7).

For genes with biallelic variants, the cumulative binomial probability was calculated[18]. Biallelic variants in *CELSR2* were identified in 8 cases, which was significantly more than expected by chance after Bonferroni correction (1% MAF cutoff for biallelic damaging missense genotypes in *CELSR2*, 8 versus 0.0029, Pc = 0.011). Biallelic *SPTBN5* variants were identified in 5 cases, which was not significantly more than expected by chance after Bonferroni correction (0.5% MAF cutoff for biallelic damaging missense genotypes in *SPTBN5*, 5 versus 0.0016, Pc = 0.87).

To analyze the significance of biallelic variants in the cases, we established a control cohort that included 1942 asymptomatic parents from trios. The frequencies of

biallelic variants in 8 genes (*CELSR2, ADGRA1, CCDC66, AKAP13, CRMP1, MICAL2, SYNJ2,* and *TOGARAM2*) were significantly higher than those in asymptomatic parent controls (Fig. 2 and Supplementary Table 8), among which 4 genes (*CELSR2, CRMP1, ADGRA1,* and *AKAP13*) met all four criteria on the gene profile (step 4 in Fig. 1).

Additionally, 5 hemizygous variants in *TENM1* were identified in 6 unrelated cases (Table 1). These variants did not present as hemizygotes or homozygotes in the controls of the general population.

Genetic-clinical features of the patients with variants in novel candidate genes.

SBF1. Four missense variants in *SBF1* (MIM*603560) were identified in four unrelated cases, including three *de novo* variants (c.337C>A/p.Gln113Lys, c.4459G>A/p.Gly1487Ser, and c.5424G>C/p.Trp1808Cys) and one with unknown origin (adopted, c.2272A>G/p.Ile758Val) (Fig. 3a and the DNA sequencing chromatograms in Extended Data Fig. 2a). The four variants were not present in the controls of the gnomAD-all population or in our 296 healthy controls. In addition to the significant excesses of *de novo* variants (Supplementary Table 7), the aggregate frequencies of the variants in the cases were significantly higher than those in the controls (4/468 vs. 0/109408 in the controls of the gnomAD-all population, $P = 3.25 \times 10^{-10}$; vs. 0/9046 in the controls of the gnomAD-East Asian population, $P = 5.78 \times 10^{-6}$; vs. 0/592 in our 296 normal controls, $P = 0.038$, Supplementary Table 9).

Three *de novo* missense variants (p.Gln113Lys, p.Gly1487Ser, and

p.Trp1808Cys) were located at the functional domains, i.e., the tripartite differentially expressed in normal and neoplastic cells (DENN) domain, the myotubularin phosphatase domain, and the pleckstrin homology (PH) domain, respectively (Fig. 3a). They were predicted to alter hydrogen bonding with surrounding residues (Extended Data Fig. 2b). The variant p.Ile758Val was located in the region between DENN and Glucosyltransferases, Rab-like GTPase activators and Myotubularins (GRAM) domain (Fig. 3a) without hydrogen bond changes by protein modeling but was predicted to decrease the protein stability (Extended Data Fig. 2b).

The clinical features of the four cases are summarized in Table 2. The three patients (LG90, LG57, and LG241) with *de novo* variants located in the functional domains exhibited intractable and frequent seizures even under a combination of three or four anti-epileptic drugs (AEDs). They presented both generalized and multifocal discharges in EEGs. The patient (LG206) with the variant in the region between the DENN and GRAM domains (p.Ile758Val) presented a relatively late onset age (10-14 years) with only generalized discharges in EEG. He achieved seizure-free with monotherapy of lamotrigine, despite previous daily myoclonic seizures.

CELSR2. Biallelic variants in *CELSR2* (MIM*604265) were identified in eight unrelated cases, including a homozygous missense variant (c.7227C>A/p.His2409Gln) in two cases and six compound heterozygous missense variants (c.1763C>G/p.Pro588Arg & c.8545G>A/p.Glu2849Lys, c.3640A>T/p.Ser1214Cys & c.6108C>G/p.Phe2036Leu, c.4411C>A/p.Pro1471Thr & c.5969G>A/p.Arg1990His, c.6986G>A/p.Ser2329Asn & c.3640A>T/p.Ser1214Cys, c.8551A>G/p.Ser2851Gly &

c.3329C>T/p.Thr1110Ile, and c.8624G>A/p.Arg2875Gln &

c.6313A>T/p.Thr2105Ser) (Fig. 3b and the DNA sequencing chromatograms in

Extended Data Fig. 3a). The variant p.Ser1214Cys was also recurrently identified in

two unrelated cases. All heterozygous variants presented no or low allele frequencies

in the gnomAD database (criteria in step 3 in Fig. 1). In addition to the significant

excess of recessive variants, the frequency of biallelic variants in the cases were

significantly higher than that in the asymptomatic parent controls (Fig 2).

Additionally, the aggregate frequencies of the variants in the cases were significantly

higher than those in the controls (16/468 vs. 496/81210 in the controls of the

gnomAD-all population, $P = 6.61 \times 10^{-8}$; vs. 113/8124 in the controls of the

gnomAD-East Asian population, $P = 2.35 \times 10^{-3}$; vs. 3/592 in our 296 normal controls,

$P = 5.91 \times 10^{-4}$, Supplementary Table 10).

Four of the twelve missense variants were located at the functional domains,

including two (p.Pro588Arg and p.Thr1110Ile) in the cadherin EGF LAG seven-pass

G-type receptor (CELSR) repeat domains, one (p.Pro1471Thr) in the laminin G-like

domain, and one (p.Ser2329Asn) in the G-protein-coupled receptor proteolytic site

(GPS) domain. The other eight variants were located in the nonfunctional regions,

including one (p.Ser1214Cys) in the region between the CELSR repeats and EGF-like

domain, three (p.Arg1990His, p.Phe2036Leu, and p.Thr2105Ser) in the region

between the laminin G-like and GPS domains, one (p.His2409Gln) located in the

transmembrane region, and three (p.Glu2849Lys, p.Ser2851Gly, and p.Arg2875Gln)

located in the C-terminal intracellular region (Fig. 3b). Among the eight pairs of

biallelic variants, at least one of the paired missense variants was predicted to affect hydrogen bonding or decrease protein stability (Extended Data Fig. 3b).

The clinical features of the eight cases are listed in Table 2. The two cases (LG38 and LG231) with homozygous variant p.His2409Gln exhibited intractable seizures. In contrast, the two cases (LG242 and LG40) with compound heterozygous variants that had both variants located at nonfunctional regions (p.Ser1214Cys & p.Phe2036Leu and p.Thr2105Ser & p.Arg2875Gln) achieved seizure-free with monotherapy of valproate/lamotrigine. Among the other four cases with one of the paired variants located in the functional domains, two cases (LG150 and LG238, who had variants p.Thr1110Ile and p.Ser2329Asn in functional domains, respectively) presented refractory seizures; one case (LG230, with p.Pro1471Thr in the laminin G-like domain) achieved seizure-free but had intellectual disability; and the other case (LG54) achieved seizure-free without intellectual disability and had compound heterozygous variants with two variants located furthest apart (p.Pro588Arg and p.Glu2849Lys, a distance of 2261 amino acids), which have been suggested to be associated with phenotype severity[32,33].

TENM1. Five hemizygous missense variants in *TENM1* (MIM*10178) were identified in six unrelated cases, including c.467A>G/p.Asp156Gly, c.503G>A/p.Cys168Tyr, c.638C>T/p.Ala213Val, c.3326C>T/p.Thr1109Met, and c.5246T>C/p.Val1756Ala (Fig. 3c and the DNA sequencing chromatograms in Extended Data Fig. 4a). All *TENM1* hemizygous variants were inherited from their asymptomatic mothers, consistent with an XLR inheritance pattern. No

hemizygotes/homozygotes of the variants were present in the controls of the gnomAD-all population. The aggregate frequencies of the variants in this cohort were significantly higher than those in the male controls (6/163 vs. 0/2549 in the hemizygote controls of the gnomAD-all population, $P = 4.32 \times 10^{-8}$; vs. 0/251 in the hemizygote controls of the gnomAD-East Asian population, $P = 3.5 \times 10^{-3}$, Supplementary Table 11).

Three variants (p.Asp156Gly, p.Cys168Tyr, and p.Ala213Val) were located at the N-terminal intracellular teneurin domain, one variant (p.Thr1109Met) was located in the extracellular region between EGF-like repeats and ncl-1, HT2A and lin-41 (NHL) repeats, and one variant (p.Val1756Ala) was located in the extracellular region between Tyr and Asp dipeptide (YD) 5 and YD 6 domains (Fig. 3c).

Among the three cases with variants in the N-terminal intracellular teneurin domain, two cases (LG239 and LG60) suffered from refractory seizures even under three AEDs. In contrast, the three cases (LG28, LG189, and LG270) with variants located in the nonfunctional regions achieved seizure-free under the combination therapy of valproate and lamotrigine.

Seizure activity in *Sbf*, *Flamingo*, and *Ten-m* knockdown *Drosophila*. To validate the association between the three novel candidate genes and epilepsy, we established a gene knockdown model in *Drosophila* by RNA interference (RNAi). The *Drosophila* homologs of the human *SBF1*, *CELSR2*, and *TENM1* genes are *Sbf*, *Flamingo*, and *Ten-m*, respectively. The RNAi efficiency of the three genes in flies

was detected by reverse transcription quantitative PCR (RT-qPCR). Compared to WT flies, mRNA expression of the three genes in the knockdown flies was reduced by 47% (*Sbf*), 75% (*Flamingo*), and 79% (*Ten-m*) (Extended Data Fig. 5). We examined bang-sensitivity (BS) seizure-like behavior in *tub-Gal4>Sbf-*, *Flamingo-*, and *Ten-m-RNAi* flies. Three phases of typical seizure-like behavior in the BS test, including seizure, paralysis, and recovery, were observed in the knockdown flies (Fig. 4a). Seizure-like behaviors were detected in 40.2% (*Sbf*), 24.8% (*Flamingo*), and 33.0% (*Ten-m*) of the knockdown flies, which was 8, 3, and 4 times higher than the control flies, respectively (Fig. 4b). The gene knockdown flies also showed a longer duration of seizure-like behavior than the controls. The knockdown flies recovered from seizures within 30 (*Sbf*), 7 (*Flamingo*), and 20 (*Ten-m*) seconds, while the control flies recovered within 3, 5, and 5 seconds, respectively (Fig. 4c).

Projection neurons (PNs) are important excitatory neurons in the central nervous system of *Drosophila*[34]. We examined the effect of gene deficiencies on the electrophysiological activity of PNs by using whole-cell recording (Fig. 5a). The *Sbf*, *Flamingo*, and *Ten-m* knockdown flies showed regular bursts of firing in the PNs (Fig. 5b). The frequencies of spontaneous excitatory postsynaptic potentials (sEPSPs) in knockdown flies were significantly higher than those in WT flies (Fig. 5c). There was no significant difference in the amplitude of sEPSPs between the knockdown flies and WT flies (Fig. 5d). These results suggested that knockdown of *Sbf*, *Flamingo*, and *Ten-m* resulted in significantly increased seizure susceptibility and epileptic electrophysiological activity in *Drosophila*.

Seizure activity in *sbf1* knockout zebrafish. To further determine the potential pathogenic roles of *SBF1*, we generated a *sbf1* (the zebrafish homolog of *SBF1*) knockout model using CRISPR/Cas9 technology in zebrafish. SET binding factor 1 (encoded by *SBF1*) in humans and zebrafish is 70% identical. A germline mutation with a 4-nt (TGGA) deletion was introduced in exon 3 of the primary *sbf1* transcript (RefSeq: NM_001045158.1), resulting in a premature stop codon in exon 5 (Extended Data Fig. 6a). Using RT-qPCR, we confirmed that there was an absence of 88% of total *sbf1* mRNA in *sbf1*$^{-/-}$ and 41% of total *sbf1* mRNA in *sbf1*$^{+/-}$ zebrafish, proving the efficiency of the *sbf1* knockout (Extended Data Fig. 6b). At 5 days postfertilization (d.p.f.), morphological abnormalities, including lack of a swim bladder, severe body curvature, and small body size, were observed in 1.1% of *sbf1*$^{-/-}$ and 0.9% of *sbf1*$^{+/-}$ larvae (Fig. 6a, b). At 17 d.p.f., all *sbf1*$^{-/-}$ zebrafish were dead, while *sbf1*$^{+/-}$ and *sbf1*$^{+/+}$ siblings remained alive. Approximately 62.5% of *sbf1*$^{+/-}$ and 83.3% of *sbf1*$^{+/+}$ zebrafish survived to 30 d.p.f., suggesting an essential role of *sbf1* in survival (Fig. 6c).

We next examined seizure-like behavior in *sbf1* knockout zebrafish. Seizure-like behavior characterized by high-speed (> 20 mm/sec) "whirlpool-like" circling swimming was observed in the *sbf1*$^{+/-}$ and *sbf1*$^{-/-}$ larvae at 7 d.p.f. (Fig. 6d). It was noted that the *sbf1*$^{+/-}$ larvae exhibited more hyperactive/seizure-like behavior with a longer distance of high-speed movement than the *sbf1*$^{+/+}$ larvae (Fig. 6e), with significant differences between *sbf1*$^{+/-}$ and *sbf1*$^{+/+}$ larvae in the 20 to 60 min

observations. In contrast, the *sbf1*[-/-] larvae exhibited more hyperactive/seizure-like behavior with a significantly longer distance of high-speed movement than the *sbf1*[+/+] larvae at only the 60 min observation (Fig. 6e). Similarly, the *sbf1*[+/-] larvae exhibited a longer duration of high-speed movement than the *sbf1*[+/+] larvae (Fig. 6f). We further performed electrophysiological recordings in the forebrain of larvae at 7-10 d.p.f. as reported previously[28]. Spontaneous epileptiform discharges were recorded in *sbf1*[-/-] and *sbf1*[+/-] larvae but not in *sbf1*[+/+] larvae (Fig. 6g). Both the *sbf1*[-/-] and *sbf1*[+/-] larvae exhibited a greater number and duration of discharges than the *sbf1*[+/+] larvae (Fig. 6h, i). These results suggest that deficiency of *sbf1* is potentially associated with seizure-like electrophysiological activity in zebrafish.

Spontaneous seizure and electroencephalography recording in *Celsr2* knockout mice. *Celsr2*, a core planar cell polarity (PCP) component, plays versatile roles in neural development, including cilia organization, neuron migration, and axon navigation[35]. To validate the potential role of *CELSR2* in seizures, we generated a *Celsr2* knockout model by inserting a targeting vector containing an internal ribosomal entry site (IRES) and the LacZ gene into exon 23 of the *Celsr2* gene to interrupt its transcription as described previously[29]. The *Celsr2*[+/+] mice did not show seizures or epileptiform discharges on video-EEG recordings (Fig. 7a). In contrast, spontaneous seizures with typical EEG alterations were observed in 4 of the *Celsr2*[-/-] mice (4/15, 26.7%, Fig. 7b, c, and Supplementary Video). The average duration of seizure activity in the *Celsr2*[-/-] mice was 194.9 ± 168.0 seconds (mean ± SD, Fig. 7d).

Among the four *Celsr2*[-/-] mice with spontaneous seizures, two mice exhibited seizures to stage 3. The other two mice displayed seizures up to stage 5, followed by death (Fig. 7e). Analysis of the power spectra of the background EEGs showed that the *Celsr2*[-/-] mice had higher spectral power, characterized by high-amplitude and low-frequency oscillations (Fig. 7f).

Discussion

The development of high-throughput sequencing techniques has enabled genetic studies with large cohorts. However, these studies have encountered challenges in discovering novel pathogenic genes[12-14] in recent years. The gene-disease associations in more than three-fourths of the human genome remain undetermined (https://omim.org). The present study focused on LGS, an epileptic encephalopathy of childhood onset, and used trio-based WES with individualized analysis before statistical studies, which includes individualized analysis of each trio by explainable inheritance origin with stratified MAF filtration and individualized analysis of each gene from four aspects. Three novel candidate genes for LGS were identified, including *SBF1* with *de novo* origin, *CELSR2* with biallelic recessive inheritance, and *TENM1* with X-linked recessive inheritance. These genes presented significant repetitiveness, including significantly higher excesses of *de novo* variants in *SBF1* and biallelic variants in *CELSR2*, and aggregated frequencies of variants in *SBF1*, *CELSR2*, and *TENM1* compared with that in the controls of the gnomAD population. The frequency of compound heterozygous/homozygous *CELSR2* variants in the cases

was significantly higher than that in the asymptomatic parent controls. Clinically, the phenotype severity was correlated with the genotype. Animal models with knockdown or knockout of these genes exhibited increased seizure-like behavior and increased firing of excitatory neurons. This study suggested that *SBF1*, *CELSR2,* and *TENM1* were pathogenic genes of LGS and highlights the implication of phenotype subclassification and individualized analysis of trios in combination with specified statistical analysis in identifying novel pathogenic genes.

Epilepsy syndromes are characterized by age-dependent clinical manifestations, especially the onset age[1], which are potentially associated with distinct pathogenic genetic causes[16]. The present study focused on LGS, the epileptic encephalopathy of childhood onset with characteristic clinical manifestations, differing from most of the DEEs that are commonly of early onset and used to be generally named EIEE. Consistently, this study identified three novel potential pathogenic genes, i.e., *SBF1*, *CELSR2,* and *TENM1*, which accounted for 7.7% (18/235) of cases, in addition to *CHD2*, which was ranked at the top of the pathogenic genes (10/235) in this cohort, differing from the DEEs in which *SCN1A* was the most common pathogenic gene[12-14]. Recent studies with large cohorts have encountered challenges in identifying novel pathogenic genes for epileptic encephalopathies[12-14]. The present study identified three pathogenic genes of LGS from 235 cases, which is the largest cohort of LGS so far, to our knowledge. More importantly, targeting LGS, a characteristic epilepsy syndrome with distinct clinical features, potentially decreased the heterogeneity of the subjects and improved the efficiency of detection. Therefore, this study reinforces the

implication of phenotype subclassification by fining clinical features, which is potentially suggestive for genetic studies of large cohorts.

Statistical analysis is generally used to detect potential pathogenic variants/genes in genetic studies with large cohorts[12-14]. This study employed an individualized analysis procedure before statistical burden analyses, which potentially improves the specificity and sensitivity. After general filtrations, variants with explainable inheritance origin in each trio were selected, which potentially improved the specificity. The variants were then filtered with MAF criteria according to the inheritance pattern. The MAF of *de novo* variants, hemizygotes, and homozygotes was set as absent in the control populations in gnomAD, and the filtration MAF for compound heterozygotes was set at $< 1 \times 10^{-6}$ for the product of multiplying the frequencies of two alleles in gnomAD. This measure aimed to avoid omission of a single low-MAF variant in biallelic variants and potentially improved the sensitivity. Such a single heterozygous variant with low MAF alone is not pathogenic but is potentially pathogenic when it appears as one of the paired biallelic variants, including those in homozygotes/hemizygotes. For gene profile filtration, the four criteria for genes potentially improve specificity in identifying novel candidate genes. Specific statistical analyses were used for variants of different inheritance, including the Poisson cumulative distribution function for *de novo* variants and the cumulative binomial probability for recessive variants. For the compound heterozygous variants, it is currently unknown how frequently compound heterozygous variants are present in normal populations. We therefore established a control cohort that included 1942

asymptomatic parents from trios for analysis of compound heterozygous variants. *SBF1*, *CELSR2,* and *TENM1* were then selected as novel potentially pathogenic genes for LGS and subjected to further studies.

SBF1 (MIM*603560) encodes a member of the protein-tyrosine phosphatase family, which plays a vital role in cell growth and differentiation[36]. Previously, *SBF1* recessive variants were reported to be associated with Charcot-Marie-Tooth disease type 4B3 (CMT4B3, OMIM*615284), which is characterized by progressive limb muscle weakness and distal sensory impairment[37]. *SBF1* is expressed in the brain and muscle at similar levels, suggesting functional roles in the brain. In mice, homozygous knockout of *Sbf1* causes postnatal lethality with incomplete penetrance[38]. In this study, three *de novo* heterozygous *SBF1* missense variants were identified, which showed a significant excess of *de novo* variants and significantly higher aggregated frequencies of variants in the LGS cohort than in the controls of gnomAD populations. In animal experiments, *Sbf1* knockdown flies and knock-out zebrafish showed seizure-like behavior and increased firing of excitatory neurons. Clinically, *SBF1* variants in the functional domains were associated with a relatively severe phenotype, whereas the variant between domains resulted in late-onset seizures with a good prognosis, indicating a genotype-phenotype correlation. These findings suggested that *SBF1* is potentially associated with epilepsy. It is noted that the heterozygous *Sbf1* knockout zebrafish presented more hyperactive/seizure-like behavior than the homozygous knockout larvae. Additionally, the probability of being loss of function intolerant (pLI) of *SBF1* is 1.00, indicating that *SBF1* is highly

intolerant to heterozygous loss-of-function variants. These evidences potentially suggest an association between epilepsy and heterozygous *SBF1* variants.

Previously, the CMT4B3-associated variants were all biallelic recessive variants, including biallelic missense variants and biallelic truncation variants (Extended Data Fig. 7). The present study showed that *Sbf1* homozygous knockout in zebrafish causes premature death. Similarly, *Sbf1* homozygous knockout in mice causes postnatal lethality with incomplete penetrance[38]. The *Sbf1* homozygous knockout mice did not present overt motor or gait deficiencies, although an approximately 10% reduction in the number of myelinated axons in the sciatic nerve was observed[39]. Therefore, the mechanism underlying the pathogenesis of CMT4B3 caused by *SBF1* biallelic variants is unclear. Gene expression across multiple tissues is common, and subsequently, a gene is potentially associated with multiple phenotypes. An example is *DYNC1H1* (MIM*600112), which is associated with both CMT and abnormalities of the brain[40], including epilepsy. Among the patients with phenotypes caused by *DYNC1H1* variants, 36% (59/164) presented abnormalities of the brain, including seizures in 36 patients (22%); 26% (43/164) of patients presented only CMT; and 38% (62/164) of patients presented both CMT and abnormalities of the brain (data from the HGMD, https//www.hgmd.cf.ac.uk). Although the location and damage effect of variants are suspected to play roles[40,41], the distinct mechanism underlying the phenotype variation is unknown. Our recent study on *PCDH15*, which is associated with deafness and epilepsy, showed that the distinct phenotypes are associated with the tissue-specific gene expression stage[42]. Further studies are

required to determine the specific mechanisms underlying the distinct phenotypes of *SBF1*.

CELSR2 (MIM*604265) encodes cadherin EGF LAG seven-pass G-type receptor 2 (CELSR2), a transmembrane protein of the flamingo subfamily. Our previous studies have shown that two CELSR subfamily genes, *CELSR1* and *CELSR3*, are associated with epilepsy[43,44]. *CELSR2* is highly expressed in the brain with predominance in early life and plays a vital role in cell/cell signaling during nervous system formation[35]. The loss of function observed/expected upper bound fraction (LOEUF) of *CELSR2* is 0.25 (LOEUF < 0.35), and the pLI is 1.00, indicating that *CELSR2* variants with loss of function are potentially pathogenic. In this study, we identified eight pairs of biallelic *CELSR2* variants in the LGS cohort, which showed a significant excess of biallelic variants genome-wide, significantly higher aggregated frequencies of variants than that in the controls of gnomAD populations, and a significantly higher frequency of compound heterozygous/homozygous variants in the cases than that in asymptomatic parent controls. The *CELSR2* homozygous variants and compound heterozygous variants with one of the paired variants located at the functional domains were associated with a severe phenotype, whereas compound heterozygous variants with both variants located at nonfunctional regions were associated with a relatively milder phenotype, suggesting a genotype-phenotype correlation. The *Celsr2* knock-down flies and knock-out mice showed seizure-like behavior and increased firing of excitatory neurons. These findings suggest that *CELSR2* is potentially associated with epilepsy.

TENM1 (MIM*10178) encodes a transmembrane teneurin subfamily protein that is highly expressed in the brain, predominantly during the prenatal and mature stages. TENM1 is involved in neural development by regulating the establishment of proper connectivity within the nervous system[45,46]. The LOEUF of the *TENM1* gene was 0.19 (LOEUF < 0.35), and the pLI was 1.00, indicating that loss of function of *TENM1* is potentially pathogenic. This study identified hemizygous *TENM1* variants in six unrelated cases. No hemizygotes/homozygotes of the variants were present in the controls of gnomAD populations, and the aggregate frequencies of the hemizygotes were significantly higher than those in the male controls. Two patients with hemizygous variants located in the N-terminal intracellular teneurin domain presented refractory seizures, while the patients with variants located in nonfunctional regions achieved seizure-free, suggesting a genotype-phenotype correlation. *Tenm1* knockdown flies exhibited an increased seizure-like behavior rate and increased excitability of neurons in the present study. These findings indicated that *TENM1* was potentially associated with epilepsy.

Additionally, 35 novel genes (in 44 cases) met the six criteria in individualized analysis, including inheritance pattern and stratified MAF, gene expression in the brain, defined genotype not against epilepsy, high pLI/pRec, and abnormal phenotypes produced by KO/KD. The majority (82.9%, 29/35) of the genes showed a recessive inheritance pattern, among which three genes (*ADGRA1, AKAP13,* and *CRMP1*) presented higher frequencies of recessive variants compared to the asymptomatic parent controls. These genes are potential candidate genes of epilepsy,

for which further studies are required.

Among the novel candidate genes, *SBF1* presents dominant inheritance (heterozygous *de novo* variants in three cases), and the remaining majority of candidate genes present recessive inheritance, including XLR. This could be basically understood by the quantitative dependent feature of genes[47,48]. We defined the lowest limit of the required quantity of genetic function of the gene as the genetic dependent quantity (GDQ). If the full scale of GDQ was set at 100% with contributions from two copies of a gene, the genes with GDQ < 50% are much more abundant (https://gdap.org.cn/)[47,48], since the human genome is diploid and usually a portion of functioning from one copy of a gene is sufficient for biophysiological function. Subsequently, pathogenic recessive (including X-linked recessive) variants are potentially common. By utilizing trio-based sequencing, this study was designed to detect variants of different origin, including those of recessive origin, which occur in genes with GDQ < 50%. The subsequent stratified MAF filtration, instead of a clear cut-off of MAF as "absent from populations", ensured the inclusion of heterozygous variants of low MAF, of which a single variant alone is not pathogenic but is potentially pathogenic when it appears as one of the paired biallelic variants. In fact, a single heterozygous variant of "damaging" in recessive disorders is not "pathogenic" and thus may be prevalent with low MAF in the general population, typically p. Arg208Ter (MAF of 0.00025) and c.509-1G>C (MAF of 0.00039) in *TPP1,* which were identified in 89% of patients with ceroid lipofuscinosis[49], a severe neurodegenerative disease with epilepsy. Therefore, special attention is required to

recessive variants in designing protocols to identify the underlying causes of genetic disorders, including the application of controls for compound heterozygous variants.

In conclusion, the present study identified three novel pathogenic genes of childhood epileptic encephalopathy, *SBF1* with *de novo* dominance inheritance, *CELSR2* with biallelic recessive inheritance, and *TENM1* with X-linked recessive inheritance, which were validated by genetic knockdown/knockout experiments. This study highlights the implication of phenotype subclassification, individualized analysis of trios in combination with specified statistical analysis, and setting controls for compound heterozygous variants.

References

1. Wirrell, E.C. *et al.* Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions. *Epilepsia* **63**, 1333-1348 (2022).
2. Eltze, C.M. *et al.* A population-based study of newly diagnosed epilepsy in infants. *Epilepsia* **54**, 437-45 (2013).
3. Asadi-Pooya, A.A. Lennox-Gastaut syndrome: a comprehensive review. *Neurol Sci* **39**, 403-414 (2018).
4. Jahngir, M.U., Ahmad, M.Q. & Jahangir, M. Lennox-Gastaut Syndrome: In a Nutshell. *Cureus* **10**, e3134 (2018).
5. Specchio, N. *et al.* International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE Task Force on Nosology and Definitions. *Epilepsia* **63**, 1398-1442 (2022).
6. Sheidley, B.R. *et al.* Genetic testing for the epilepsies: A systematic review. *Epilepsia* **63**, 375-387 (2022).
7. Ruggiero, S.M., Xian, J. & Helbig, I. The current landscape of epilepsy genetics: where are we, and where are we going? *Curr Opin Neurol* **36**, 86-94 (2023).
8. Epi, K.C. *et al.* De novo mutations in epileptic encephalopathies. *Nature* **501**, 217-21 (2013).
9. Carvill, G.L. *et al.* Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. *Nature Genetics* **45**, 825-830 (2013).
10. Euro, E.-R.E.S.C., Epilepsy Phenome/Genome, P. & Epi, K.C. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. *Am J Hum Genet* **95**, 360-70 (2014).

11.   Shi, Y.W. *et al.* Synaptic clustering differences due to different GABRB3 mutations cause variable epilepsy syndromes. *Brain* **142**, 3028-3044 (2019).

12.   Epi25 Collaborative. Electronic address, s.b.u.e.a. & Epi, C. Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. *Am J Hum Genet* **105**, 267-282 (2019).

13.   Epi25, C., Chen, S., Neale, B.M. & Berkovic, S.F. Shared and distinct ultra-rare genetic risk for diverse epilepsies: A whole-exome sequencing study of 54,423 individuals across multiple genetic ancestries. Preprint at *medRxiv* https://doi.org/10.1101/2023.02.22.23286310 (2023).

14.   Epi25 Collaborative. Electronic address, j.c.c.e. & Epi, C. Sub-genic intolerance, ClinVar, and the epilepsies: A whole-exome sequencing study of 29,165 individuals. *Am J Hum Genet* **108**, 965-982 (2021).

15.   Wang, J. *et al.* UNC13B variants associated with partial epilepsy with favourable outcome. *Brain* **144**, 3050-3060 (2021).

16.   Wang, J. *et al.* Epilepsy-associated genes. *Seizure* **44**, 11-20 (2017).

17.   Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* **17**, 405-24 (2015).

18.   Martin, H.C. *et al.* Quantifying the contribution of recessive coding variation to developmental disorders. *Science* **362**, 1161-1164 (2018).

19.   Strande, N.T. *et al.* Evaluating the Clinical Validity of Gene-Disease Associations: An Evidence-Based Framework Developed by the Clinical Genome Resource. *Am J Hum Genet* **100**, 895-906 (2017).

20.   Ni, J.Q. *et al.* A genome-scale shRNA resource for transgenic RNAi in Drosophila. *Nat Methods* **8**, 405-7 (2011).

21.   Parker, L., Howlett, I.C., Rusan, Z.M. & Tanouye, M.A. Seizure and epilepsy: studies of seizure disorders in Drosophila. *Int Rev Neurobiol* **99**, 1-21 (2011).

22.   Perkins, K.L. Cell-attached voltage-clamp and current-clamp recording and stimulation techniques in brain slices. *J Neurosci Methods* **154**, 1-18 (2006).

23.   Gu, H. & O'Dowd, D.K. Cholinergic synaptic transmission in adult Drosophila Kenyon cells in situ. *J Neurosci* **26**, 265-72 (2006).

24.   Pena, I.A. *et al.* Pyridoxine-Dependent Epilepsy in Zebrafish Caused by Aldh7a1 Deficiency. *Genetics* **207**, 1501-1518 (2017).

25.   Hwang, W.Y. *et al.* Efficient genome editing in zebrafish using a CRISPR-Cas system. *Nat Biotechnol* **31**, 227-9 (2013).

26.   Sander, J.D. *et al.* ZiFiT (Zinc Finger Targeter): an updated zinc finger engineering tool. *Nucleic Acids Res* **38**, W462-8 (2010).

27.   Baraban, S.C., Taylor, M.R., Castro, P.A. & Baier, H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. *Neuroscience* **131**, 759-68 (2005).

28.   Baraban, S.C. Forebrain electrophysiological recording in larval zebrafish. *J Vis Exp* https://doi.org/10.3791/50104 (2013).

29.   Tissir, F. *et al.* Lack of cadherins Celsr2 and Celsr3 impairs ependymal ciliogenesis, leading to fatal hydrocephalus. *Nat Neurosci* **13**, 700-7 (2010).

30.   Lin, T.W. *et al.* Regulation of Synapse Development by Vgat Deletion from ErbB4-Positive Interneurons. *J Neurosci* **38**, 2533-2550 (2018).

31. Chen, W. *et al.* Neddylation stabilizes Nav1.1 to maintain interneuron excitability and prevent seizures in murine epilepsy models. *J Clin Invest* **131**(2021).

32. Luo, S. *et al.* Recessive LAMA5 Variants Associated With Partial Epilepsy and Spasms in Infancy. *Front Mol Neurosci* **15**, 825390 (2022).

33. Luo, J. *et al.* MPDZ variants associated with epilepsies and/or febrile seizures and the individualized genotype-phenotype correlation. *Genes & Diseases* https://doi.org/10.1016/j.gendis.2023.06.006 (2023).

34. Olsen, S.R., Bhandawat, V. & Wilson, R.I. Excitatory interactions between olfactory processing channels in the Drosophila antennal lobe. *Neuron* **54**, 89-103 (2007).

35. Wen, Q. *et al.* Inactivating Celsr2 promotes motor axon fasciculation and regeneration in mouse and human. *Brain* **145**, 670-683 (2022).

36. Cui, X. *et al.* Association of SET domain and myotubularin-related proteins modulates growth control. *Nat Genet* **18**, 331-7 (1998).

37. Nakhro, K. *et al.* SET binding factor 1 (SBF1) mutation causes Charcot-Marie-Tooth disease type 4B3. *Neurology* **81**, 165-73 (2013).

38. Firestein, R. *et al.* Male infertility, impaired spermatogenesis, and azoospermia in mice deficient for the pseudophosphatase Sbf1. *J Clin Invest* **109**, 1165-72 (2002).

39. Mammel, A.E. *et al.* Distinct roles for the Charcot-Marie-Tooth disease-causing endosomal regulators Mtmr5 and Mtmr13 in axon radial sorting and Schwann cell myelination. *Hum Mol Genet* **31**, 1216-1229 (2022).

40. Becker, L.L. *et al.* The clinical-phenotype continuum in DYNC1H1-related disorders—genomic profiling and proposal for a novel classification. *Journal of Human Genetics* **65**, 1003-1017 (2020).

41. Hoang, H.T., Schlager, M.A., Carter, A.P. & Bullock, S.L. DYNC1H1 mutations associated with neurological diseases compromise processivity of dynein–dynactin–cargo adaptor complexes. *Proceedings of the National Academy of Sciences* **114** (2017).

42. Lin, S.M. *et al.* PCDH15 in self-limited partial epilepsy and the mechanism of distinct phenotypes. *Annals of Neurology* **Revised** (2023).

43. Chen, Z. *et al.* CELSR1 variants are associated with partial epilepsy of childhood. *Am J Med Genet B Neuropsychiatr Genet* **189**, 247-256 (2022).

44. Li, J. *et al.* CELSR3 variants are associated with febrile seizures and epilepsy with antecedent febrile seizures. *CNS Neurosci Ther* **28**, 382-389 (2022).

45. Minet, A.D., Rubin, B.P., Tucker, R.P., Baumgartner, S. & Chiquet-Ehrismann, R. Teneurin-1, a vertebrate homologue of the Drosophila pair-rule gene ten-m, is a neuronal protein with a novel type of heparin-binding domain. *J Cell Sci* **112 (Pt 12)**, 2019-32 (1999).

46. Mosca, T.J., Hong, W., Dani, V.S., Favaloro, V. & Luo, L. Trans-synaptic Teneurin signalling in neuromuscular synapse organization and target choice. *Nature* **484**, 237-41 (2012).

47. He, N. *et al.* Common genetic epilepsies, pathogenicity of genes/variants, and genetic dependence. *Seizure* **109**, 38-39 (2023).

48. Li, B. *et al.* Genetic Dependence and Genetic Diseases. Preprint at *bioRxiv* https://doi.org/10.1101/2023.08.02.551736 (2023).

49. Kousi, M., Lehesjoki, A.E. & Mole, S.E. Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses. *Hum Mutat* **33**, 42-63 (2012).

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgements

We thank the affected patients and their families for participating in this study. This work was funded by the National Natural Science Foundation of China (grant nos. 82171439, 82271505, and 81971216) and the Guangdong Basic and Applied Basic Research Foundation (grant no. 2021A1515010986). The funders had no role in the study design, data collection, and analysis or in the decision to publish or the preparation of the manuscript.

Author Contributions

WPL and YWS conceptualized the study, analyzed and interpreted the data, and drafted and revised the manuscript. WPL had full access to all data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. JGZ, NH, ZLY, NXS, and HKL performed the clinical data and whole-exome sequencing analysis. WBL, XCQ, and CXF performed seizure activity studies. WPL, YWS, JGZ, NH, ZLY, NXS, HKL, WBL, XCQ, and CXF drafted and revised the manuscript and contributed to the statistical analysis. All authors collected data, revised the manuscript, and contributed to the writing.

Competing interests

All authors claim that there are no conflicts of interest.

Ethics statement

All procedures performed were in accordance with the ethical standards of the institutional committee. Ethical approval was approved by the ethics committee of the Second Affiliated Hospital of Guangzhou Medical University (approval ethics number 2020-hs-49). We declared that all patients' IDs were not identified to anyone outside the research group.

Table 1. Summary of potential pathogenic variants

Known epilepsy-associated genes (number of cases, 53 in total)

   Genes with pathogenic or likely pathogenic variants (47):

     Epilepsy/DEE genes (24):

     CHD2 (10)[a], *SETD1B* (4)[a], *CELF2* (2), *PCDH19* (2), *GABRB3* (1), *GRIN2B* (1), *KCNB1* (1), *NSF* (1), *SCN1A* (1), *STXBP1* (1).

     Genes associated with developmental disorder with seizures (23):

     ATP1A3 (2), *CACNA1B*[b] (2), *NUS1* (2), *SRCAP* (2), *SYNGAP1* (2), *TSC1* (2), *ZMYM2* (2), *COL4A2* (1), *GRIA1* (1), *KIF1A* (1), *KMT2D* (1), *MACF1* (1), *NEXMIF* (1), *PPP2CA* (1), *SIN3A* (1), *TSC2* (1).

   Genes with possible pathogenic variants[c] (6):

     KIF4A (2), *ANK3* (1), *CNPY3* (1), *SLC7A6OS* (1), *TAF1* (1).

Novel candidate genes with repetitive variants (number of cases, 73 in total)

   ***De novo* variants (5):**

     <u>*SBF1*</u> (3)[a], <u>*SRRM2*</u> (2).

   Homozygous/compound heterozygous variants (53):

     <u>*CELSR2*</u> (8)[a,d], *SPTBN5* (5), <u>*ADGRA1*</u> (2)[d], *CCDC66* (2)[d], <u>*AKAP13*</u> (2)[d], *CFAP46* (2), *CMYA5* (2), *CRACR2A* (2), <u>*CRMP1*</u> (2)[d], <u>*FAT1*</u> (2), *FBN3* (2), <u>*LAMA1*</u> (2), <u>*LRP2*</u> (2), *MICAL2* (2)[d], *MYO7B* (2), *PDZD2* (2), *SEC16A* (2), *STARD9* (2), *SYNJ2* (2)[d], *TOGARAM2* (2)[d], *UTRN* (2), *ZNF721* (2).

   X-linked recessive variants (15):

     <u>*TENM1*</u> (6), *ZNF674* (3), <u>*AMER1*</u> (2), *MAGEC1* (2), <u>*NRK*</u> (2).

[a]Genes with a significant excess of variants in this cohort compared with controls (*Pc* < 0.05 after Bonferroni correction). [b]The two variants in the *CACNA1B* gene were *de novo*, while previously reported variants were recessive. [c]The variants in these genes were all recessive and evaluated as uncertain significance by ACMG but were considered to be possibly pathogenic by highly consistent clinical phenotype as previously reported, absence or very low MAF in the general population (criteria in step 3 in Fig. 1), and explainable inheritance origin. [d]The frequencies of genes with biallelic variants in this cohort were significantly higher than those in the asymptomatic parent controls (*P* < 0.05).

The underline indicates the genes that also met the four criteria on the gene profile in step 4 for filtration of novel candidate genes (Fig. 1).

Table 2. Clinical features of the patients with variants in *SBF1*, *CELSR2*, and *TENM1*

No.	Variants	Sex	Age	Onset age	Seizure course	EEG	Brain MRI	Development	AEDs	Prognosis
SBF1 (*603560; NM_002972.4; autosomal dominant)										
LG90	c.337C>A/ p.Gln113Lys	M	Teenagers	Toddlers	Spasms 2-4 times/d for 1 mo, tonic 3-20 times/d	GPSW; multifocal SW; Ictal: spasms, tonic	NA	ID	VPA, TPM, LTG	Refractory
LG57	c.4459G>A/ p.Gly1487Ser	F	Teenagers	Childhood	aAb 2-3 times/d, CPS 10 times/d	Fast rhythm during sleep; generalized 1.5-2.5 Hz SW; multifocal spikes	Normal	Normal	VPA, LTG, PHT	Refractory
LG241	c.5424G>C/ p.Trp1808Cys	M	Teenagers	Infants	Tonic10-20 times/d; GTCS 4-5 times/d	GPSW; multifocal SW	Normal	Normal	VPA, PB, CBZ, PHT	Refractory
LG206	c.2272A>G/ p.Ile758Val[a]	M	Teenagers	Childhood	Myoclonic daily; aAb; GTCS once	Fast rhythm during sleep; GPSW; generalized 1.5-2.5 Hz SW	Normal	Normal	LTG	Seizure free for 4 yrs
CELSR2 (*604265; NM_001408.2; autosomal recessive)										
LG38	c.7227C>A/ p.His2409Gln c.7227C>A/ p.His2409Gln	M	Teenagers	Childhood	GTCS, 1-2 times/mo	Fast rhythm during sleep; GPSW	Normal	Normal	CBZ, VPA	Refractory
LG231	c.7227C>A/ p.His2409Gln c.7227C>A/ p.His2409Gln	M	Teenagers	Toddlers	Tonic, CPS, sGTCS, 6-15 times/d	Generalized polyspikes; GPSW; right frontal SW; Ictal: tonic, CPS	Normal	Normal	VPA, LTG, OXC, TPM	Refractory
LG54	c.1763C>G/ p.Pro588Arg c.8545G>A/ p.Glu2849Lys	F	Teenagers	Childhood	CPS, sGTCS 1-2 times/mo	Generalized fast rhythm during sleep; GPSW	Normal	Normal	LEV, LTG	Seizure free for 2 yrs
LG242	c.3640A>T/ p.Ser1214Cys	M	Teenagers	Toddlers	Status of tonic, FS, GTCS 2-6	Fast rhythm during sleep; GPSW	Normal	Normal	VPA	Seizure free for 1 yr

	c.6108C>G/ p.Phe2036Leu				times/yr for 4 yrs					
LG230	c.4411C>A/ p.Pro1471Thr c.5969G>A/ p.Arg1990His	F	Teena gers	Childh ood	Tonic daily; GTCS once at age 7 yrs and recurred 1-2 times/mo at age 18 yrs	Generalized fast rhythm during sleep; GPSW; right frontal-temporal SW	Normal	ID	VPA, LTG	Seizure free for 3 yrs
LG238	c.6986G>A/ p.Ser2329Asn c.3640A>T/ p.Ser1214Cys	M	Child hood	Toddle rs	Spasms and tonic 2-3 times/d	Generalized fast rhythm during sleep; GPSW; left frontal-temporal SW; Ictal: spasms, tonic	Normal	DD, ID	TPM, VPA, CNZ	Refractory
LG150	c.8551A>G/ p.Ser2851Gly c.3329C>T/ p.Thr1110Ile	F	Child hood	Infants	Spasms 2-4 times/d for 8 mos, tonic 4-5 times/d	Generalized polyspikes, 1-2 Hz GPSW; Ictal: spasms, tonic	Normal	DD, ID	VPA, LEV	Refractory
LG40	c.8624G>A/ p.Arg2875Gln c.6313A>T/ p.Thr2105Ser	M	Child hood	Childh ood	Myoclonic daily; sGTCS 6-7 times	Generalized polyspikes, 2.5-3 Hz GPSW; Ictal: myoclonic	Normal	Normal	LTG	Seizure free for 3 yrs

TENM1 (*300588; NM_001163278.1; X-linked recessive)

LG239	c.467A>G/ p.Asp156Gly	M	Child hood	Childh ood	GTCS 3 times at age 3 yrs, recurred 2-3 times/wk at age 5 yrs, CPS 1-2 times/mo	Generalized polyspikes; GPSW; multifocal SW; Ictal: CPS	Normal	DD, ID	LEV, VPA, LCM	Refractory
LG10	c.503G>A/ p.Cys168Tyr	M	Teena gers	Childh ood	Tonic 2-4 times/d; FS once at 2 yrs, GTCS 3 times/mo	Generalized fast rhythm during sleep; GPSW; Ictal: tonic	Normal	Normal	LTG, VPA, LEV	Seizure free for 10 yrs
LG60	c.638C>T/ p.Ala213Val	M	Teena gers	Childh ood	CPS or aAb daily	Generalized fast rhythm during sleep; multifocal SW	Normal	Normal	LTG, VPA, LEV	Refractory
LG28	c.3326C>T/ p.Thr1109Met	M	Teena gers	Childh ood	Tonic and atonic 10-15 times/d for 5 yrs	GPSW; Ictal: tonic, atonic	Normal	ID	VPA, LTG	Seizure free for 12 yrs

| LG189 | c.3326C>T/ p.Thr1109Met | M | Child hood | Childh ood | Tonic 4-12 times/d; CPS 4-10 times/yr | Generalized fast rhythm during sleep; GPSW; left temporal SW; Ictal: tonic, CPS | Normal | Normal | VPA, LTG | Seizure free for 6 mos |
| LG270 | c.5267T>C/ p.Val1756Ala | M | Child hood | Childh ood | Tonic daily; GTCS 3-4 times | Generalized fast rhythm during sleep; GPSW; multifocal polyspikes and SW | Normal | DD, ID | VPA, LTG | Seizure free for 1 yr |

aAb, atypical absences; AEDs, antiepileptic drugs; CBZ, carbamazepine; CNZ, clonazepam; CPS, complex partial seizure; d, day; DD, developmental delay; EEG, electroencephalogram; F, female; FS, febrile seizure; GPSW, generalized polyspike-slow waves; GTCS, generalized tonic-clonic seizure; ID, intelligence disorder; LEV, levetiracetam; LTG, lamotrigine; M, male; mo, month; MRI, magnetic resonance imaging; NA, not available; OXC, oxcarbazepine; PB, phenobarbital; PHT, phenytoin; PSW, polyspike-slow waves; sGTCS, secondary generalized tonic–clonic seizure; SW, spike-slow waves; TPM, topiramate; VPA, valproate; wk, week; yr, year.

aVariant with unknown origin.

Fig. 1 │ A flow chart of trio-based whole-exome sequencing with an individualized analytical framework. Abbreviations: ACMG, American College of Medical Genetics and Genomics guideline; KO/KD, knockout/knockdown; MAF, minor allele frequency.

Fig. 2 │ The frequencies of biallelic variants in LGS compared with those in the asymptomatic parent controls. The orange dots indicate the frequencies of genes with biallelic variants in cases. The blue dots indicate the frequencies of genes with biallelic variants in asymptomatic parent controls. The genes in red font indicate that the frequencies of biallelic variants in cases were significantly higher than those in the asymptomatic parent controls. Data were analyzed by two-tailed Fisher's exact test.

Fig. 3 | *SBF1*, *CELSR2*, and *TENM1* variants identified in patients with LGS.

Pedigrees of the unrelated cases with *SBF1* (**a**), *CELSR2* (**b**), and *TENM1* (**c**) variants (top) and the localization of the variants in the protein domains (bottom). The gray dotted lines in (**b**) indicate a pair of compound heterozygous variants of *CELSR2*. Abbreviations: CELSR, cadherin EGF LAG seven-pass G-type receptor; DENN, differentially expressed in normal and neoplastic cells; EGF, epidermal growth factor; GPS, G-protein-coupled receptor proteolytic site; GRAM, glucosyltransferases, Rab-like GTPase activators and myotubularins; NHL, ncl-1, HT2A and lin-41; PH, pleckstrin homology; YD, Tyr and Asp dipeptide.

Fig. 4│Seizure-like behaviors in *Sbf*, *Flamingo*, and *Ten-m* knockdown *Drosophila*. a, Three stages of seizure-like behaviours in the (bang-sensitivity) BS paralysis test, including seizure (manifesting as vibrating wings), paralysis, and recovery, were observed in *Sbf*, *Flamingo*, and *Ten-m* knockdown flies. **b,** Seizure-like behaviors occurred at a higher rate in the knockdown flies (*tub-Gal4>Sbf-/Flamingo-/Ten-m-RNAi*) than in WT flies (*Canton-S*), *tub-Gal4* (*Control*), and the respective RNAi control flies. **c,** The recovery time from seizures in the knockdown flies (*tub-Gal4>Sbf-/Flamingo-/Ten-m-RNAi*) and in the control groups. Data were collected from 4-7 groups, 4-6 flies in each group, for BS paralysis and recovery tests. All data are represented as the mean ± s.e.m. One-way ANOVA and Tukey's post hoc test were used for multiple comparisons.

Fig. 5 | Knockdown of *Sbf*, *Flamingo*, and *Ten-m* induces neural excitability in projection neurons of *Drosophila*. a, Whole-cell recording in the fly brain. Left, a schematic diagram showing the insert position of a glass microelectrode in an immobilized isolated brain (scale bar, 100 μm). Right, cell bodies of the squared region in the left panel are indicated at higher magnification (scale bar, 10 μm) and were targeted for whole-cell recording in the living isolated brain preparation. **b,** Representative traces of electrical activity in projection neurons (PNs) showing spontaneous excitatory postsynaptic potentials (sEPSPs) of WT and *tub-Gal4>Sbf-/Flamingo-/Ten-m-RNAi* flies. **c,** Frequencies of sEPSPs in PNs of WT and knockdown flies. **d,** Amplitude of sEPSPs between WT and knockdown flies. The box plots show all data points from minimum to maximum. Boxes represent data

from the lower (25th percentile) to the upper (75th percentile) quartiles. The box

center corresponds to the 50th percentile. A horizontal line indicates the median. Data

are represented as the mean ± s.e.m. (*Canton-S*, n = 7; *tub-Gal4>Sbf-RNAi*, n = 8;

tub-Gal4>Flamingo-RNAi, n = 7, *tub-Gal4>Ten-m-RNAi*, n = 8), from three

independent experiments; one-way ANOVA test.

Fig. 6│Seizure activity in *sbf1* knockout zebrafish. **a,** Malformation was observed

in 5 days post-fertilization (d.p.f.) larvae of *sbf1*⁺/⁻ and *sbf1*⁻/⁻ but not *sbf1*⁺/⁺ (WT). **b,**

The malformation rates in the *sbf1*⁺/⁻ and *sbf1*⁻/⁻ larvae were significantly higher than

those in *sbf1*⁺/⁺ larvae (n = 8, one-way ANOVA); *sbf1*⁺/⁺ (grey), *sbf1*⁺/⁻ (blue), and

sbf1⁻/⁻ (orange). **c,** Kaplan–Meier survival analysis for *sbf1*⁺/⁺ (n = 18), *sbf1*⁺/⁻ (n = 24),

and *sbf1*⁻/⁻ (n = 15). **d,** Representative swimming tracks of 7 d.p.f. larvae within 60

minutes. Red, green, and black lines represent high- (≥ 20 mm/s), intermediate- (8 -

20 mm/s), and slow-speed movements (< 8 mm/s), respectively. **e, f,** Distance (**e**) and

duration (**f**) of high-speed movement in each genotype. Data are represented as the

mean ± s.e.m. (*sbf1*⁺/⁺, n = 10; *sbf1*⁺/⁻, n = 20; *sbf1*⁻/⁻, n = 10), from three independent

experiments; one-way ANOVA test. **g,** Extracellular field recordings were performed

in immobilized and agar-embedded zebrafish larvae forebrains. Left panel, schematic showing the insert position of a glass microelectrode. Right panel, representative field recording trace of epileptiform discharge from $sbf1^{+/+}$ (top), $sbf1^{+/-}$ (middle), and sbf$1^{-/-}$ (bottom) larvae at 7 d.p.f. **h, i,** Total number of electrographic seizure-like bursts (including interictal and ictal discharges) (**h**) and duration of the discharges (**i**). Data were from 15 min of recording in 7-11 d.p.f. larvae of $sbf1^{+/+}$ (n = 22), $sbf1^{+/-}$ (n = 27), and $sbf1^{-/-}$ (n = 13); Kruskal-Wallis test.

Fig. 7 │ Spontaneous seizures and electroencephalography (EEG) recording in

***Celsr2* knockout mice. a,** Normal EEGs were detected from the WT mice. **b,** A

representative trace shows ictal epileptiform discharges in *Celsr2^-/-^* mice. The dotted

boxes indicate the zoomed-in traces of the onset and ictal epileptiform discharges.

The green arrows indicate the time point of behavior of the mouse from video

recording. **c,** The proportion of *Celsr2^+/+^* and *Celsr2^-/-^* mice exhibiting spontaneous

seizures. **d,** Seizure duration in *Celsr2^+/+^* (n = 10) and *Celsr2^-/-^* (n = 4) mice;

Mann-Whitney test. **e,** Seizure behaviors were rated with a modified Racine scale in

Celsr2$^{+/+}$ and *Celsr2*$^{-/-}$ mice. **f,** Power spectrum analysis of EEG signals in *Celsr2*$^{+/+}$

and *Celsr2*$^{-/-}$ mice.

Extended Data Fig. 1│General information of the variants after filtration by inheritance origin and stratified MAF. a, Pie chart of the inheritance origin of the 1112 qualified variants. **b,** The distribution of the number of *de novo*, homozygous, compound heterozygous, and hemizygous variants per case.

Extended Data Fig. 2│Genetic data of cases with *SBF1* variants. a, Sanger sequencing verification of four cases with *SBF1* variants. **b,** Modeling of *SBF1* missense variants indicated abnormal hydrogen bonds. Wild-type and mutant residues are colored green and light magenta, respectively. Hydrogen bonds are colored orange. The variant Lys113 rebuilds two hydrogen bonds with Asp100 and Glu99. Ser1487 rebuilds one with His1488. The variant 1808Cys destroyed one hydrogen bond with His1823. Variants that altered the stability of the global conformation of the SBF1 protein were indicated by the value of free energy stability changes (ΔΔG, Kcal/mol) using online tools (http://gpcr.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi). An absolute value of ΔΔG > 0.5 indicates a large decrease in stability. The variants in red font (the top) indicate that the variant changed hydrogen bonds with surrounding amino acid residues. The ΔΔG in red font (bottom) indicates that the variant significantly changed the protein stability.

Extended Data Fig. 3│Genetic data of cases with *CELSR2* variants. a, Pedigrees

and Sanger sequencing verification of the eight cases with biallelic *CELSR2* variants.

b, Modelling of CELSR2 missense variants indicated abnormal hydrogen bonds.

Wild-type and mutant residues are colored green and light magenta, respectively.

Hydrogen bonds are colored orange. Variants that destabilized the global

conformation of the CELSR2 protein were indicated by the value of free energy

stability changes (ΔΔG, Kcal/mol) using online tools

(http://gpcr.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi). An

absolute value of ΔΔG > 0.5 indicates a large decrease in stability. The variants in red

font (the top) indicate that the variant changed hydrogen bonds with surrounding

amino acid residues. The ΔΔG in red font (bottom) indicates that the variant

significantly changed the protein stability.

Extended Data Fig. 4│Genetic data of cases with *TENM1* variants. a, Pedigrees and Sanger sequencing verification of the six cases with *TENM1* variants. **b,** Modelling of TENM1 missense variants predicted abnormal hydrogen bonds. Wild-type and mutant residues are colored green and light magenta, respectively. Hydrogen bonds are colored orange. The variant Tyr168 rebuilds a hydrogen bond with His151. Variants that destabilized the global conformation of the TENM1 protein were indicated by the value of free energy stability changes (ΔΔG, Kcal/mol) using online tools (http://gpcr.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi). An absolute value of ΔΔG > 0.5 indicates a large decrease in stability. The variants in red font (the top) indicate that the variant changed hydrogen bonds with surrounding amino acid residues. The ΔΔG in red font (bottom) indicates that the variant significantly changed the protein stability.

Extended Data Fig. 5│The knockdown efficiency of *Sbf*, *Flamingo*, and *Ten-m* in the files. The relative mRNA levels of *Sbf*, *Flamingo*, and *Ten-m* in knockdown flies were detected by RT-qPCR. The mRNA levels of wild-type flies were normalized to 1.0. The *Gapdh* was used as an internal control. Data were analyzed by Student's t test.

Extended Data Fig. 6│Establishment of an *sbf1* KO zebrafish model using CRISPR/Cas9. a, The CRISPR/Cas9 gRNA targeted exon 3 (E3) of *sbf1*, resulting in a 4-nt (TGGA) deletion in E3. The frameshift mutation led to a stop codon in exon 5 (E5). **b,** The relative mRNA expression of *sbf1* was detected by RT-qPCR in the *sbf1*$^{+/+}$, *sbf1*$^{+/-}$, and *sbf1*$^{-/-}$ fish. The mRNA levels of *sbf1*$^{+/+}$ were normalized to 1.0. The *gapdh* was used as an internal control. Data were analyzed by Student's t test.

Extended Data Fig. 7│The localization of *SBF1* variants identified in this study and in Charcot-Marie-Tooth disease. Variants identified in this study are shown in red (the top). Variants associated with Charcot-Marie-Tooth disease are shown in blue (bottom). The gray dotted lines indicate the pairs of compound heterozygous variants of *SBF1*.